Adjuvant radiotherapy in pT3–4N0M0 major salivary gland Cancer without other adverse features
4 LAY SUMMARY: pT3-4N0M0 major salivary gland cancer without evidence of other adverse pathologic features represents a rare, moderate-risk disease category with high variation in treatment strategies depending on histopathology and physician and patient preferences. Our study of this disease category suggests that adjuvant radiotherapy is associated with higher 5-year overall survival.
Authors
- Russell Maxwell
- Ryan M. Carey (ORCID: https://orcid.org/0000-0002-0186-2265)
- Jake J. Lee (ORCID: https://orcid.org/0000-0002-8175-9486)
- Aman M. Patel (ORCID: https://orcid.org/0000-0003-0794-041X)
- Robert M. Brody (ORCID: https://orcid.org/0000-0001-6639-8830)
- Jason A. Brant (ORCID: https://orcid.org/0000-0002-3492-0679)
- Afash Haleem (ORCID: https://orcid.org/0000-0001-7268-6142)
- Praneet C. Kaki (ORCID: https://orcid.org/0009-0005-6428-2064)
Institutions
- Rutgers, The State University of New Jersey (US)
- Thomas Jefferson University (US)
- Philadelphia VA Medical Center (US)
- Rutgers New Jersey Medical School (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- American Journal of Otolaryngology
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1016/j.amjoto.2025.104628
- Citations
- 1
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01